OR WAIT null SECS
Catalent has acquired the Vaccine Manufacturing Innovation Centre in Harwell, Oxford to expand its biologics capabilities across the UK and Europe.
Catalent announced on April 6, 2022 that it has acquired Vaccine Manufacturing and Innovation Centre UK Limited’s biologics development and manufacturing facility currently under construction near Oxford, United Kingdom. Catalent plans to invest up to US$160 million (£120 million) into the completion of the construction of the facility.
The focus of the facility will be to develop and manufacture biologic therapies and vaccines, including messenger RNA, proteins, and other advances modalities. The facility is expected to employ more than 400 people once completed as well as support public and private organizations looking to develop and manufacture biotherapeutics.
Catalent’s workforce in the UK already exceeds 1300 people at its four facilities, located in Nottingham, Swindon, Haverhill, and Dartford. The company also has sites in Italy, Belgium, France, Switzerland, and the United States.
“This acquisition allows Catalent to collaborate with the rich academic and biomedical science community centered around Oxford, with its world-class talent, and will result in a facility that provides opportunities to transform innovation into real treatments for patients across the United Kingdom, Europe, and beyond,” commented Mike Riley, president of Catalent Biotherapeutics, in a press release. “Our priority is to complete construction as soon as possible to be able to commence customer programs in 2022. We will then integrate its capabilities within our existing network of biologics facilities across Europe to offer a flexible range of manufacturing, technology, and development solutions for the pipeline of thousands of development programs currently underway.”